Journal Review in Thoracic Surgery: Adjuvant Therapy in Lung Adenocarcinoma

Behind The Knife: The Surgery Podcast

Science, Health & Fitness, Medicine, Education

4.8 • 1.4K Ratings

🗓️ 22 November 2021

⏱️ 24 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

November is Lung Cancer Awareness Month, and what better way is there to spend your time than getting to know the recent advances in adjuvant therapy for early-stage lung adenocarcinoma?

Learning Objectives

- Review work-up and treatment of lung adenocarcinoma
- Review evidence behind Osimertinib as an adjuvant therapy in EGFR mutation positive disease
- Review recent advances in gene expression profiles for targeted application of adjuvant chemotherapy
- Discuss future directions for research
- Discuss additional advancements in diagnosis, monitoring, and immunotherapy

Referenced Material

- Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020; 383:1711-1723. DOI: 10.1056/NEJMoa2027071 https://www.nejm.org/doi/full/10.1056/NEJMoa2027071
- Woodard GA, Wang SX, Kratz JR, et al. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer 2018;19(1):58-64. DOI: 10.1016/j.cllc.2017.05.015
https://www.clinical-lung-cancer.com/article/S1525-7304(17)30150-X/fulltext
- Woodard GA, Kratz JR, Haro G, et al. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clin Lung Cancer. 2021;20:S1525-7304(21)00212-6. DOI: 10.1016/j.cllc.2021.08.008
https://www.clinical-lung-cancer.com/article/S1525-7304(21)00212-6/fulltext

Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.

Transcript

Click on a timestamp to play from that location

0:00.0	behind the knife the surgery podcast where we take a behind the scenes intimate look at surgery
0:06.0	from leaders in the field.
0:21.2	Hello and welcome back. This is your thoracic team from Swedish Medical Center in Seattle with
0:26.0	myself Megan Lennahan joined by the esteemed doctors Brian Louis and Peter White. Hello.
0:33.5	Today we will be talking about some recent advancements in the management of early stage adenocarcinoma
0:39.5	of the lung. Dr. White in particular has been so excited for this episode. Dr. White would you
0:45.1	like to speak briefly about why you are so enthused? Thanks Megan. So lung cancer continues to be the
0:51.2	deadliest cancer in the United States by a huge margin. In fact if you look at mortality and you
0:56.8	add up the next three highest cancers colon breast and prostate it's higher than all three combined.
1:03.1	Even for early stage disease not only do we see that high mortality but there's such a wide
1:08.4	range of median survival. When you look at the non-small cell lung cancer five-year survival it ranges
1:15.2	from 68 to 92 percent just for stage one and anywhere from 53 to 60 percent for stage two.
1:22.3	While surgical resection remains the mainstay of treatment for early stage non-small cell lung cancer
1:28.1	the benefit of adjuvant therapy has been much more limited. Older trials such as the Anita trial
1:34.0	and JBR-10 showed only modest improvements in survival but more substantial advances in adjuvant
1:39.9	therapy have been made just within the last few years. On today's podcast we're going to discuss
1:44.4	some of the exciting developments in targeted therapy by taking a deeper dive at the adjuvant
1:48.9	trial and this evaluates osomurtinib a tyrosine kinase inhibitor targeted to the epidermal growth
1:55.4	factor receptor or EGFR and it's benefit for stage one B to three A patients with EGFR mutations.
2:03.6	Then we'll present two new papers that use a 14 gene expression profile to identify early stage
2:10.1	patients who are likely to benefit from adjuvant cytotoxic chemotherapy. Before we dive into
2:15.9	anything further I want to mention that none of us have any financial disclosures or relationships
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Behind The Knife: The Surgery Podcast, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Behind The Knife: The Surgery Podcast and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.